Acadia Pharmaceuticals, Inc. (ACAD) Posts Q1 Loss of 12c/Share
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $22.64 +2.49%
EPS Growth %: -62.5%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -62.5%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q1 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $450 thousand versus the consensus estimate of $500 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Goldman "broadly" raises estimates for LTL and truckload stocks
- Aeroméxico Announces Webcast of Second Quarter 2026 Financial Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
